Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2015 | Research article

Theoretical analysis of headache recurrence in patients administered triptans for migraine based on receptor occupancy

Authors: Kentaro Tokuoka, Risa Takayanagi, Mioko Toyabe, Masayuki Watanabe, Yasuhisa Kitagawa, Yasuhiko Yamada

Published in: The Journal of Headache and Pain | Issue 1/2015

Login to get access

Abstract

Background

In this study, we retrospectively analyzed the relationship between headache recurrence and serotonin 5-HT1B/1D receptor occupancy (Φ1B and Φ1D). Triptans marketed in Japan (sumatriptan, zolmitriptan, eletriptan, rizatriptan, naratriptan) were investigated.

Methods

Receptor occupancies were calculated from both the pharmacokinetic and pharmacodynamic data of triptans. We examined the relationships between recurrence rate and elimination half-lives, and Ф1B and Ф1D, as calculated from the time-course of plasma drug concentration obtained from other studies. The time until Ф1B and Ф1D became 50 % or less, 40 % or less, and 30 % or less was calculated as duration time to examine the relationship with recurrence rate.

Results

For Ф1B, eletriptan remained at a low level. For Ф1D, it was indicated that all triptans obtained an occupancy of 80 % or higher at maximum. For all items, though recurrence tended to be lower along with longer half-life, no significant statistical correlation was found. For both Ф1B and Ф1D, the recurrence rate tended to be lower as the duration became longer. In addition, a significant correlation was observed for Ф1D (p < 0.05). For clarifying the Ф value and time period most closely correlated with recurrence rate, recurrence and Ф1B and Ф1D at 6, 12, and 18 h after administration were calculated. The most significant correlation was observed between recurrence rate and Ф1D at 12 h after administration (p < 0.01).

Conclusions

As an index for evaluating headache recurrence following triptan administration, recurrence rate and Ф1D value at 12 h after administration were found to be most closely correlated and useful for analysis. Our results indicate that headache recurrence inhibition can be evaluated using these values.
Literature
3.
go back to reference Takayanagi R, Tokuoka K, Suzuki Y, Watanabe M, Kitagawa Y, Yamada Y (2012) Analysis of Drug Efficacy of Sumatriptan for Acute Migraine Based on Receptor Occupancy. Japanese Journal of Headache 39(1):91–97 Takayanagi R, Tokuoka K, Suzuki Y, Watanabe M, Kitagawa Y, Yamada Y (2012) Analysis of Drug Efficacy of Sumatriptan for Acute Migraine Based on Receptor Occupancy. Japanese Journal of Headache 39(1):91–97
4.
go back to reference Tokuoka K, Takayanagi R, Suzuki Y, Watanabe M, Kitagawa Y, Yamada Y (2014) Theory-based analysis of clinical efficacy of triptans using receptor occupancy. J Headache Pain 15:85PubMedCentralPubMedCrossRef Tokuoka K, Takayanagi R, Suzuki Y, Watanabe M, Kitagawa Y, Yamada Y (2014) Theory-based analysis of clinical efficacy of triptans using receptor occupancy. J Headache Pain 15:85PubMedCentralPubMedCrossRef
5.
go back to reference Sugiura M, Sawada Y, Yamada Y, Nakamura K, Iga T (1992) Prediction of therapeutic doses of sulfonylureas based on receptor occupancy theory. Xenobio Metabo Disp 7:233–241 Sugiura M, Sawada Y, Yamada Y, Nakamura K, Iga T (1992) Prediction of therapeutic doses of sulfonylureas based on receptor occupancy theory. Xenobio Metabo Disp 7:233–241
6.
go back to reference Yamada Y, Sawada Y, Takayanagi R, Ito K, Nakamura K, Iga T (1993) Prediction of therapeutic doses of antipsychotic drugs as Dopamine D2 receptor antagonists: Approach based on receptor occupancy theory. Xenobio Metabo Disp 8:247–261 Yamada Y, Sawada Y, Takayanagi R, Ito K, Nakamura K, Iga T (1993) Prediction of therapeutic doses of antipsychotic drugs as Dopamine D2 receptor antagonists: Approach based on receptor occupancy theory. Xenobio Metabo Disp 8:247–261
7.
go back to reference Yamada Y, Matsuyama K, Takayanagi R, Kotaki H, Sawada Y, Iga T (1999) Kinetic Analysis of Therapeutic Doses of β-Blockers for Angina Pectoris Based on Receptor Occupancy Theory-Relationship between β-Receptor Occupancy or Vasodilative Action and Dose. YAKUGAKU ZASSHI 119:495–501 [in Japanese]PubMed Yamada Y, Matsuyama K, Takayanagi R, Kotaki H, Sawada Y, Iga T (1999) Kinetic Analysis of Therapeutic Doses of β-Blockers for Angina Pectoris Based on Receptor Occupancy Theory-Relationship between β-Receptor Occupancy or Vasodilative Action and Dose. YAKUGAKU ZASSHI 119:495–501 [in Japanese]PubMed
8.
go back to reference Yamada Y, Sugiura M, Higo K, Ozeki T, Takayanagi R, Okuyama K, Yamamoto K, Satoh H, Sawada Y, Iga T (2004) Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol 54:185–190PubMedCrossRef Yamada Y, Sugiura M, Higo K, Ozeki T, Takayanagi R, Okuyama K, Yamamoto K, Satoh H, Sawada Y, Iga T (2004) Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol 54:185–190PubMedCrossRef
9.
go back to reference Takayanagi R, Mizushima H, Ozeki T, Yokoyama H, Iga T, Yamada Y (2007) Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects. Biol Pharm Bull 30:1297–1300PubMedCrossRef Takayanagi R, Mizushima H, Ozeki T, Yokoyama H, Iga T, Yamada Y (2007) Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects. Biol Pharm Bull 30:1297–1300PubMedCrossRef
10.
go back to reference Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y (2009) Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. Int J Clin Oncol 14:518–524PubMedCrossRef Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y (2009) Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. Int J Clin Oncol 14:518–524PubMedCrossRef
11.
go back to reference Akarawut W, Lin CJ, Smith DE (1998) Noncompetitive Inhibition of Glycylsarcosine Transport by Quinapril in Rabbit Renal Brush Border Membrane Vesicles: Effect on High-Affinity Peptide Transporter. J Pharmacol Exp Ther 287(2):684–690PubMed Akarawut W, Lin CJ, Smith DE (1998) Noncompetitive Inhibition of Glycylsarcosine Transport by Quinapril in Rabbit Renal Brush Border Membrane Vesicles: Effect on High-Affinity Peptide Transporter. J Pharmacol Exp Ther 287(2):684–690PubMed
13.
14.
go back to reference Yamada Y, Sawada Y, Iga T (1995) Prediction of adverse effect of β-blocking agents. Jpn Pharmacol Ther 23(1):27–33 [in Japanese] Yamada Y, Sawada Y, Iga T (1995) Prediction of adverse effect of β-blocking agents. Jpn Pharmacol Ther 23(1):27–33 [in Japanese]
16.
go back to reference Perry CM, Markham A (1998) Sumatriptan. An updated review of its use in migraine. Drugs 55(6):889–922PubMedCrossRef Perry CM, Markham A (1998) Sumatriptan. An updated review of its use in migraine. Drugs 55(6):889–922PubMedCrossRef
17.
go back to reference Tomita M, Suzuki N, Sakai F (2002) The Distribution of 5-HT1B Receptors and the Effect of Anti-migraine Drugs Triptan in Trigeminovascular System of the Rat. Kitasato Med 32:173–178 [in Japanese] Tomita M, Suzuki N, Sakai F (2002) The Distribution of 5-HT1B Receptors and the Effect of Anti-migraine Drugs Triptan in Trigeminovascular System of the Rat. Kitasato Med 32:173–178 [in Japanese]
18.
go back to reference Hamada J (2010) Significance of naratriptan based on the pharmacokinetic and pharmacological profile. Progress in Medicine 30:2437–2442 [in Japanese] Hamada J (2010) Significance of naratriptan based on the pharmacokinetic and pharmacological profile. Progress in Medicine 30:2437–2442 [in Japanese]
21.
go back to reference Dixon R, Warrander A (1997) The clinical pharmacokinetics of zolmitriptan. Cephalalgia Suppl 18:15–20, PubMed PMID: 9399013 Dixon R, Warrander A (1997) The clinical pharmacokinetics of zolmitriptan. Cephalalgia Suppl 18:15–20, PubMed PMID: 9399013
25.
go back to reference Fukuuchi Y, Teramoto J, Tatsuoka Y, Yamaguchi M, Shimizu T, Urashima T, Nishioka H, Iwasaki M (2008) Clinical Evaluation of Imigran® Kit Subcutaneous Injection 3mg (Sumatriptan Succinate) in Patients with Migraine and Ciuster Headache. J Clin therapeutics Med 24(9):809–824 [in Japanese] Fukuuchi Y, Teramoto J, Tatsuoka Y, Yamaguchi M, Shimizu T, Urashima T, Nishioka H, Iwasaki M (2008) Clinical Evaluation of Imigran® Kit Subcutaneous Injection 3mg (Sumatriptan Succinate) in Patients with Migraine and Ciuster Headache. J Clin therapeutics Med 24(9):809–824 [in Japanese]
Metadata
Title
Theoretical analysis of headache recurrence in patients administered triptans for migraine based on receptor occupancy
Authors
Kentaro Tokuoka
Risa Takayanagi
Mioko Toyabe
Masayuki Watanabe
Yasuhisa Kitagawa
Yasuhiko Yamada
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-015-0558-9

Other articles of this Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue